This is the authors' abstract. We don't add key points for this paper.
• WSRP-1b has a loose and smooth surface and flake-like structure. • WSRP-1b has irregular curls, a spherical chain, and triple-helical conformation. • WSRP-1b promoted phagocytic capacity in macrophages. • WSRP-1b activated macrophages via the MAPKs and NF-κB signaling pathway. • WSRP-1b up-regulated the mRNA expression of iNOS, TNF-α, and IL-6. Our previous research demonstrated that the glucomannan WSRP-1b, which was obtained from waste biomass of Rosa Setate x Rosa Rugosa , had potent immunostimulatory activity. However, the specific mechanisms involved in the activation of RAW264.7 macrophages by WSRP-1b remain unclear. Scanning electron microscopy, atomic force microscopy and Congo red analyses revealed that WSRP-1b exhibited a flake structure with irregular curls and had a triple-helix conformation in solution. The immunostimulation assays showed that WSRP-1b could substantially enhance macrophages phagocytosis and promote the accumulation of iNOS, TNF-α, and IL-6 mRNA. Western blot analysis indicated that the expression of mitogen-activated protein kinases (MAPKs) was upregulated in WSRP-1b-induced RAW264.7 cells. Furthermore, pretreatment of RAW 264.7 cells using specific inhibitors against MAPKs and NF-κB remarkably attenuated nitric oxide production and cytokine secretion. These data suggest that WSRP-1b activates RAW264.7 macrophages via the MAPK and NF-κB signaling pathways and may be a novel immunomodulatory agent for hypoimmunity disease therapy.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: